alexa How To Tune Recombinant Protein Production In E. Coli For Enhanced Production Of Biopharmaceuticals?
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

Joint Event on 15th World Congress on Biotechnology And Biotech Industries Meet and 2nd International Conference on Enzymology and Molecular Biology
March 20-21, 2017 Rome, Italy

Oliver Spadiut
TU Wien, Austria
ScientificTracks Abstracts: J Biotechnol Biomater
DOI: 10.4172/2155-952X.C1.070
Strong induction of recombinant protein production in E. coli can lead to agglomeration of inactive product, inclusion bodies (IBs), and also imposes a high metabolic burden which can result in cell death. We developed a feeding strategy using glucose as primary carbon source, lactose as secondary carbon source and inducer to tune recombinant protein expression which leads to higher yields of soluble and active product. We successfully applied this system for the production of several biopharmaceuticals. This new feeding approach allows expression of complex products as soluble and active protein that usually results in insoluble and inactive inclusion bodies. Cell viability and growth can be prolonged by this approach which leads to higher overall yields and thus lower production costs. Thus, our strategy might make E. coli a more attractive host for the production of biopharmaceuticals in the future. The audience will get to know a platform technology for the enhanced expression of biopharmaceuticals in E. coli to accelerate bioprocess development and yield higher product titers.

Oliver Spadiut has completed his PhD in Biotechnology from BOKU University, Austria. He has done his Post-doctoral studies from KTH Royal Institute of Technology, Stockholm, Sweden. Since 2010, he has been working as an Assistant Professor in Biochemical Engineering at TU Wien, Vienna, Austria. Currently, he is the Principal Investigator of Integrated Bioprocess Development research group. He has published more than 60 papers in reputed journals and has been serving as a reviewer for many journals.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version